Published in Hepatitis Weekly, December 2nd, 2002
Although some HCCs carry estrogen receptors, the vast majority do not. Tamoxifen, an estrogen competitor, is best known for the prevention and treatment of breast cancer. Some studies of tamoxifen in HCC have yielded contradictory results. Now, new evidence from an Asian multicenter trial of high-dose tamoxifen in people with inoperable HCC should clear up some of the confusion.
During the trial, 329...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.